Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.1%

5 terminated/withdrawn out of 82 trials

Success Rate

92.8%

+6.3% vs industry average

Late-Stage Pipeline

29%

24 trials in Phase 3/4

Results Transparency

9%

6 of 64 completed trials have results

Key Signals

6 with results4 withdrawn

Enrollment Performance

Analytics

Phase 4
20(37.0%)
N/A
18(33.3%)
Phase 2
8(14.8%)
Phase 3
4(7.4%)
Phase 1
4(7.4%)
54Total
Phase 4(20)
N/A(18)
Phase 2(8)
Phase 3(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (82)

Showing 20 of 82 trials
NCT03809377Active Not Recruiting

Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)

Role: collaborator

NCT04097366Not ApplicableActive Not Recruiting

Breast Screening - Risk Adaptive Imaging for Density

Role: collaborator

NCT04665791Not ApplicableCompleted

A Human Controlled Infection Study with Neisseria Lactamica in Malian Adults

Role: collaborator

NCT04365114Completed

Patient Outcomes from Second Film-readers and Test Threshold Relaxation in Breast Screening

Role: collaborator

NCT04587050Completed

Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV

Role: collaborator

NCT03735147Phase 4Completed

Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children

Role: collaborator

NCT04271371Completed

Preventing Relapse to Smoking Among Prisoners After Release

Role: collaborator

NCT04589312Phase 2Completed

Maternal Pertussis Wholecell Responses

Role: collaborator

NCT04735419Unknown

Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease

Role: collaborator

NCT05993260Not ApplicableCompleted

Using Text Messages to Boost COVID-19 Vaccine Booking Rate

Role: collaborator

NCT02512939Not ApplicableCompleted

Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection

Role: collaborator

NCT02883972Not ApplicableWithdrawn

Childhood Influenza Immunisation Invitation Trial in Schools

Role: lead

NCT01876628Phase 4Completed

Adjunctive Clindamycin for Cellulitis: C4C Trial.

Role: collaborator

NCT03889106Terminated

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Role: collaborator

NCT03832049Phase 3Unknown

HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial

Role: collaborator

NCT04405934Not ApplicableCompleted

COG-UK Project Hospital-Onset COVID-19 Infections Study

Role: collaborator

NCT04239430Unknown

Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

Role: collaborator

NCT03069807Not ApplicableCompleted

Completion and Acceptability of Treatment Across Primary Care and the commUnity for Latent Tuberculosis

Role: collaborator

NCT04152486Phase 3Unknown

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Role: collaborator

NCT03552198Not ApplicableCompleted

Improving the Behavioural Impact of Air Quality Alerts

Role: collaborator